• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

镓-PSMA-11 PET/CT 中联合强制利尿和后期显像:对病灶显示和放射性示踪剂摄取的影响。

Combination of Forced Diuresis with Additional Late Imaging in Ga-PSMA-11 PET/CT: Effects on Lesion Visibility and Radiotracer Uptake.

机构信息

Department of Nuclear Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland; and.

Aalborg University Hospital, Universitetshospital, Aalborg, Denmark.

出版信息

J Nucl Med. 2021 Sep 1;62(9):1252-1257. doi: 10.2967/jnumed.120.257741. Epub 2021 Feb 5.

DOI:10.2967/jnumed.120.257741
PMID:33547214
Abstract

Renal excretion of some prostate-specific membrane antigen (PSMA) ligands and consequently increased bladder activity can obscure locally relapsing prostate cancer lesions in PSMA PET/CT. Furthermore, additional late imaging in PSMA PET/CT provides a useful method to clarify uncertain findings. The aim of this retrospective study was to investigate a modified imaging protocol combining late additional imaging with hydration and forced diuresis in individuals undergoing additional late scanning for uncertain lesions or low prostate-specific antigen. We compared an older protocol with a newer one. In the old protocol, patients undergoing Ga-PSMA-11 PET/CT were examined at 90 min after injection, with 1 L of oral hydration beginning at 30 min after injection and 20 mg of furosemide given intravenously at 1 h after injection, followed by additional late imaging at 2.5 h after injection without further preparation. In the new protocol, a second group received the same procedure as before, with an additional 0.5 L of oral hydration and 10 mg of furosemide intravenously 30 min before the late imaging. We examined 132 patients (76 with the old protocol and 56 with the new one) with respect to urinary bladder activity (SUV), prostate cancer lesion uptake (SUV), and lesion contrast (ratio of tumor SUV to bladder SUV for local relapses and ratio of tumor SUV to gluteal-muscle SUV for nonlocal prostate cancer lesions). Bladder activity was significantly greater for the old protocol in the late scans than for the new protocol (ratio of bladder activity at 2.5 h to bladder activity at 1.5 h, 2.33 ± 1.17 vs. 1.37 ± 0.50, < 0.0001). Increased tumor SUV and contrast were seen at 2.5 h compared with 1.5 h ( < 0.0001 for old protocol; = 0.02 for new protocol). Increased bladder activity for the old protocol resulted in decreased lesion-to-bladder contrast, which was not the case for the new protocol. Tumor-to-background ratios increased at late imaging for both protocols, but the increase was significantly lower for the new protocol. For the old protocol, comparing the 1.5-h to the 2.5-h acquisitions, 4 lesions in 4 patients (4/76 = 5.2% of the cohort) were visible at the postdiuresis 1.5-h acquisition but not at 2.5 h, having been obscured as a result of the higher bladder activity. In the new protocol, 2 of 56 (3.6%) patients had lesions visible only at late imaging, and 2 patients had lesions that could be better discriminated at late imaging. Although the combination of diuretics and hydration can be a useful method to increase the visualization and detectability of locally recurrent prostate cancer in standard Ga-PSMA-11 PET/CT, their effects do not sufficiently continue into additional late imaging. Additional diuresis and hydration are recommended to improve the visibility, detection, and diagnostic certainty of local recurrences.

摘要

前列腺特异性膜抗原(PSMA)配体的肾脏排泄,以及随之而来的膀胱活动增加,可能会使 PSMA PET/CT 中局部复发性前列腺癌病灶变得模糊。此外,PSMA PET/CT 中的额外晚期成像提供了一种有用的方法来澄清不确定的发现。本回顾性研究的目的是调查一种改良的成像方案,该方案将晚期额外成像与水化和强制利尿相结合,用于对不确定的病灶或低前列腺特异性抗原进行额外的晚期扫描。我们比较了旧方案和新方案。在旧方案中,接受 Ga-PSMA-11 PET/CT 检查的患者在注射后 90 分钟进行检查,在注射后 30 分钟开始口服 1 升水,并在注射后 1 小时静脉注射 20 毫克呋塞米,然后在注射后 2.5 小时进行额外的晚期成像,无需进一步准备。在新方案中,第二组患者接受与之前相同的程序,在晚期成像前 30 分钟额外口服 0.5 升水和静脉注射 10 毫克呋塞米。我们检查了 132 名患者(旧方案 76 名,新方案 56 名)的膀胱活动(SUV)、前列腺癌病灶摄取(SUV)和病灶对比度(局部复发肿瘤 SUV 与膀胱 SUV 的比值和非局部前列腺癌病灶肿瘤 SUV 与臀肌 SUV 的比值)。在晚期扫描中,旧方案的膀胱活动明显高于新方案(2.5 小时与 1.5 小时膀胱活动的比值,2.33 ± 1.17 与 1.37 ± 0.50, < 0.0001)。与 1.5 小时相比,2.5 小时的肿瘤 SUV 和对比度增加(旧方案 < 0.0001;新方案 = 0.02)。旧方案中较高的膀胱活动导致病灶与膀胱的对比度降低,而新方案则不是这种情况。两种方案的肿瘤与背景比值在晚期成像时均增加,但新方案的增加幅度明显较低。对于旧方案,将 1.5 小时与 2.5 小时的采集进行比较,在 4 名患者(4/76,队列的 5.2%)的 4 个病灶在利尿后 1.5 小时的采集时可见,但在 2.5 小时时不可见,由于膀胱活动较高而被掩盖。在新方案中,56 名患者中有 2 名(3.6%)仅在晚期成像时可见病灶,有 2 名患者在晚期成像时可以更好地区分病灶。尽管利尿剂和水化的联合使用可以是一种有用的方法,可增加标准 Ga-PSMA-11 PET/CT 中局部复发性前列腺癌的可视化和可检测性,但它们的效果在晚期成像中不能充分持续。建议额外使用利尿剂和水化来提高局部复发的可见性、检测和诊断确定性。

相似文献

1
Combination of Forced Diuresis with Additional Late Imaging in Ga-PSMA-11 PET/CT: Effects on Lesion Visibility and Radiotracer Uptake.镓-PSMA-11 PET/CT 中联合强制利尿和后期显像:对病灶显示和放射性示踪剂摄取的影响。
J Nucl Med. 2021 Sep 1;62(9):1252-1257. doi: 10.2967/jnumed.120.257741. Epub 2021 Feb 5.
2
Early Injection of Furosemide Increases Detection Rate of Local Recurrence in Prostate Cancer Patients with Biochemical Recurrence Referred for Ga-PSMA-11 PET/CT.早期注射呋塞米可提高 Ga-PSMA-11 PET/CT 检查疑似生化复发前列腺癌患者局部复发的检出率。
J Nucl Med. 2021 Nov;62(11):1550-1557. doi: 10.2967/jnumed.120.261866. Epub 2021 Mar 12.
3
More advantages in detecting bone and soft tissue metastases from prostate cancer using F-PSMA PET/CT.使用F-PSMA PET/CT检测前列腺癌骨和软组织转移方面有更多优势。
Hell J Nucl Med. 2019 Jan-Apr;22(1):6-9. doi: 10.1967/s002449910952. Epub 2019 Mar 7.
4
Combined forced diuresis and late acquisition on [Ga]Ga-PSMA-11 PET/CT for biochemical recurrent prostate cancer: a clinical practice-oriented study.[68Ga]Ga-PSMA-11 PET/CT 延迟采集联合强力利尿在生化复发前列腺癌中的应用:一项临床实用导向的研究。
Eur Radiol. 2023 May;33(5):3343-3353. doi: 10.1007/s00330-023-09516-0. Epub 2023 Mar 9.
5
Ga-PSMA-11 PET/CT in patients with recurrent prostate cancer-a modified protocol compared with the common protocol.复发前列腺癌患者的镓-PSMA-11 PET/CT——与常规方案相比的改良方案
Eur J Nucl Med Mol Imaging. 2020 Mar;47(3):624-631. doi: 10.1007/s00259-019-04548-5. Epub 2019 Nov 1.
6
Impact of forced diuresis with furosemide and hydration on the halo artefact and intensity of tracer accumulation in the urinary bladder and kidneys on [Ga]Ga-PSMA-11-PET/CT in the evaluation of prostate cancer patients.在评估前列腺癌患者时,呋塞米和水化的强制利尿对 [Ga]Ga-PSMA-11-PET/CT 中膀胱和肾脏的光晕伪影以及示踪剂积聚强度的影响。
Eur J Nucl Med Mol Imaging. 2021 Jan;48(1):123-133. doi: 10.1007/s00259-020-04846-3. Epub 2020 May 8.
7
Matched-Pair Comparison of Ga-PSMA-11 and F-rhPSMA-7 PET/CT in Patients with Primary and Biochemical Recurrence of Prostate Cancer: Frequency of Non-Tumor-Related Uptake and Tumor Positivity.镓-PSMA-11 和 F-rhPSMA-7 PET/CT 在初发和生化复发前列腺癌患者中的配对比较:非肿瘤相关摄取和肿瘤阳性的频率。
J Nucl Med. 2021 Aug 1;62(8):1082-1088. doi: 10.2967/jnumed.120.251447. Epub 2020 Dec 4.
8
The Clinical Impact of Additional Late PET/CT Imaging with Ga-PSMA-11 (HBED-CC) in the Diagnosis of Prostate Cancer.镓标记的PSMA-11(HBED-CC)额外晚期PET/CT成像在前列腺癌诊断中的临床影响
J Nucl Med. 2017 May;58(5):750-755. doi: 10.2967/jnumed.116.183483. Epub 2017 Jan 6.
9
Early PET imaging with [68]Ga-PSMA-11 increases the detection rate of local recurrence in prostate cancer patients with biochemical recurrence.使用[68]Ga-PSMA-11进行早期PET成像可提高生化复发的前列腺癌患者局部复发的检出率。
Eur J Nucl Med Mol Imaging. 2017 Sep;44(10):1647-1655. doi: 10.1007/s00259-017-3743-z. Epub 2017 Jun 6.
10
Ga-PSMA I&T PET/CT for assessment of prostate cancer: evaluation of image quality after forced diuresis and delayed imaging.镓-前列腺特异性膜抗原摄取与转运正电子发射断层扫描/计算机断层扫描用于前列腺癌评估:强制利尿和延迟成像后图像质量的评估
Eur Radiol. 2016 Dec;26(12):4345-4353. doi: 10.1007/s00330-016-4308-4. Epub 2016 Mar 24.

引用本文的文献

1
Bladder activity of different PSMA PET radioligands and impact of furosemide.不同前列腺特异性膜抗原(PSMA)正电子发射断层扫描(PET)放射性配体的膀胱活性及呋塞米的影响
Res Sq. 2025 May 8:rs.3.rs-6537072. doi: 10.21203/rs.3.rs-6537072/v1.
2
Impact of delayed pelvic imaging on the staging of biochemical recurrence in prostate cancer patients using [F]DCFPYL PET/CT: a retrospective evaluation.延迟盆腔成像对使用[F]DCFPYL PET/CT的前列腺癌患者生化复发分期的影响:一项回顾性评估
EJNMMI Rep. 2025 Feb 1;9(1):5. doi: 10.1186/s41824-025-00238-8.
3
The impact of long axial field of view (LAFOV) PET on oncologic imaging.
长轴向视野(LAFOV)正电子发射断层扫描(PET)对肿瘤成像的影响。
Eur J Radiol. 2025 Feb;183:111873. doi: 10.1016/j.ejrad.2024.111873. Epub 2024 Dec 4.
4
Comparison of clinical performance between late and standard total-body [ Ga]Ga-PSMA-11 in biochemical recurrent prostate cancer.晚期与标准全身[镓]Ga-PSMA-11在生化复发前列腺癌中的临床性能比较。
Eur J Nucl Med Mol Imaging. 2025 Mar;52(4):1249-1256. doi: 10.1007/s00259-024-06980-8. Epub 2024 Nov 14.
5
The superior detection rate of total-body [Ga]Ga-PSMA-11 PET/CT compared to short axial field-of-view [Ga]Ga-PSMA-11 PET/CT for early recurrent prostate cancer patients with PSA < 0.2 ng/mL after radical prostatectomy.全身 [Ga]Ga-PSMA-11 PET/CT 比短轴向视野 [Ga]Ga-PSMA-11 PET/CT 对根治性前列腺切除术后 PSA<0.2ng/mL 的早期复发性前列腺癌患者的检测率更高。
Eur J Nucl Med Mol Imaging. 2024 Jul;51(8):2484-2494. doi: 10.1007/s00259-024-06674-1. Epub 2024 Mar 22.
6
The image quality and feasibility of solitary delayed [ Ga]Ga-PSMA-11 PET/CT using long field-of-view scanning in patients with prostate cancer.在前列腺癌患者中使用长视野扫描进行孤立性延迟[镓]Ga-PSMA-11 PET/CT的图像质量和可行性。
EJNMMI Res. 2024 Feb 6;14(1):14. doi: 10.1186/s13550-024-01076-8.
7
The accuracy and intra- and interobserver variability of PSMA PET/CT for the local staging of primary prostate cancer.PSMA PET/CT在原发性前列腺癌局部分期中的准确性及观察者内和观察者间的变异性。
Eur J Nucl Med Mol Imaging. 2024 May;51(6):1741-1752. doi: 10.1007/s00259-024-06594-0. Epub 2024 Jan 26.
8
Quantitative and Qualitative Assessment of Urinary Activity of F-Flotufolastat-PET/CT in Patients with Prostate Cancer: a Post Hoc Analysis of the LIGHTHOUSE and SPOTLIGHT Studies.F-Flotufolastat-PET/CT 尿活动的定量和定性评估:LIGHTHOUSE 和 SPOTLIGHT 研究的事后分析。
Mol Imaging Biol. 2024 Feb;26(1):53-60. doi: 10.1007/s11307-023-01867-w. Epub 2023 Nov 6.
9
Enhancing PSMA PET/CT imaging of prostate cancer: investigating the impact of multiple time point evaluation, diuretic administration, cribriform pattern, and intraductal carcinoma.提高 PSMA PET/CT 成像在前列腺癌中的应用:探究多时间点评估、利尿剂给药、筛状模式和导管内癌的影响。
Ann Nucl Med. 2023 Nov;37(11):618-628. doi: 10.1007/s12149-023-01864-7. Epub 2023 Oct 3.
10
Total-body [ Ga]Ga-PSMA-11 PET/CT improves detection rate compared with conventional [ Ga]Ga-PSMA-11 PET/CT in patients with biochemical recurrent prostate cancer.全身 [68Ga]Ga-PSMA-11 PET/CT 与常规 [68Ga]Ga-PSMA-11 PET/CT 相比,可提高生化复发性前列腺癌患者的检出率。
Eur J Nucl Med Mol Imaging. 2023 Nov;50(13):4096-4106. doi: 10.1007/s00259-023-06355-5. Epub 2023 Aug 14.